Bio-Rad Laboratories, Inc.

What they do

Bio-Rad operates in two segments: Life Science and Clinical Diagnostics, selling over 12,000 products globally. Life Science products are used in research, biopharmaceutical manufacturing, and quality control. Clinical Diagnostics products include diagnostic test systems, informatics, and quality controls for labs. The company has direct operations in over 36 countries outside the U.S.

Revenue drivers

• Clinical Diagnostics — Generates approximately 60% of net sales. Recurring revenue from installed diagnostic systems through test kits and consumables. Growth driven by quality systems, diabetes, and blood typing products.
• Life Science — Generates approximately 40% of net sales. Sells instruments and reagents for research and biopharma manufacturing, with digital PCR instruments growing more than 20% in Q2 2026.
• International markets — Approximately 60% of net sales generated internationally, with Europe the largest region. Revenue is largely in local currencies, so FX affects reported results.

Recent performance

In Q2 2026, net sales were $651.0 million, essentially flat year-over-year, but down 1.9% on a currency-neutral basis. Life Science sales fell 4.1% (down 5.1% currency-neutral), while Clinical Diagnostics rose 2.6% (up 0.3% currency-neutral). Net income was $371.4 million, or $13.85 diluted EPS, aided by a fair market value gain on Sartorius AG. Operating cash flow was $98.7 million. For the six months ended June 30, 2026, net margin was -12.5% due to a fair market value loss.

Strategy

Management focuses on driving growth through product innovation, particularly digital PCR, and expanding in clinical diagnostics. They are disciplined on capital allocation, repurchasing approximately $32 million of shares in Q2 2026. They aim for durable margin expansion and long-term shareholder value creation. They reaffirmed their full-year outlook.

Risks

• International operations — Over 60% of sales from international locations; exposure to FX, tariffs, and regulatory complexity increases costs and risks.
• Geopolitical and macro headwinds — Middle East conflict has adversely impacted EMEA demand and logistics, and China market remains uncertain, pressuring sales.
• Dependence on government and biotech funding — Reduced government funding and challenges among small biotech companies limit growth opportunities.
• Equity investment volatility — Large swings in the fair value of Sartorius AG investment cause major fluctuations in net income and EPS.

Outlook

For full-year 2026, management expects non-GAAP, currency-neutral revenue to decline approximately 3.0% to grow approximately 0.5%, with non-GAAP operating margin of 10.0% to 12.0%. They anticipate continued adverse impact from Middle East conflicts on EMEA for the rest of 2026 and expect current challenging conditions in academic research and China to persist.